Weight Loss Market Index Has Shifted Holdings
The VettaFi index added new pharmaceutical firms as researchers pivot toward oral pills and muscle-sparing treatments.
Updated on Sept. 21, 2026 in Weight Loss
Live Poll
Is now a good time for you to invest in targeted medical innovation funds?
The VettaFi Weight Loss Drug & Treatment Index completed a scheduled rebalance on September 18, 2026, dropping some firms while adding Gilead Sciences and Structure Therapeutics. This adjustment reflects a broader shift in the weight-loss drug market toward specialized oral therapies and monthly dosing regimens.
Why it matters
The rebalance tracks a growing pharmaceutical industry focus on developing next-generation weight-loss medications, including muscle-sparing treatments. Industry projections indicate the global weight-loss drug market could reach $150 billion by 2035.
The index rebalance, performed on September 18, 2026, updated constituent weights to align with current sector development. It is unknown how these specific portfolio changes will impact future volatility compared to the 17.9% one-year fund gain.
The players
Eli Lilly
A pharmaceutical giant that develops glucagon-like peptide-1 receptor agonists for metabolic health.
AstraZeneca
A global biopharmaceutical company focusing on oncology and cardiovascular metabolic drug development.
Roche Holding
A healthcare company that recently invested in the development of muscle-sparing weight-loss therapies.
Gilead Sciences
A biopharmaceutical firm added to the index that focuses on therapeutic advancements.
Structure Therapeutics
A biotechnology firm added to the index that specializes in developing oral small molecule drugs.
The details
The index administrator modified holdings to capture shifts in drug innovation, moving away from companies like Hims & Hers and toward developers of oral pills and monthly treatments. These emerging drugs often target mechanisms designed to spare muscle mass during weight loss, a key area of focus for recent licenses like those involving Roche. Manufacturers are actively streamlining dosing to improve patient adherence.
Timeline
June 2026: AstraZeneca moved its oral weight-loss pill into Phase III.
August 2026: Roche licensed a muscle-sparing weight-loss drug.
September 18, 2026: The index rebalance occurred.
Early 2027: Eli Lilly plans to file Retatrutide with the FDA.
2035: Projected weight-loss drug market size is $150 billion.
Health Landscape
The VettaFi Weight Loss Drug & Treatment Index provides a market-level gauge of pharmaceutical investment trends that reflects the shifting priorities of drug manufacturers. This update marks a strategic pivot in the weight-loss investment landscape by favoring firms pursuing oral and muscle-sparing therapies.
Readers should recognize that while these market shifts track industrial pharmaceutical progress, they do not constitute medical recommendations. Any questions regarding the availability or efficacy of new weight-loss therapies are best addressed in a conversation with your primary care physician.
The takeaway
The weight-loss drug sector is rapidly evolving toward more convenient oral medications and muscle-preserving treatments. Patients interested in learning about upcoming drug options should consult their physician regarding clinical trial progress and the expected availability of new therapies.
Further reading
For more on the current medical approaches to weight management, visit our Weight Loss section.
Live Poll
Is now a good time for you to invest in targeted medical innovation funds?
